Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

The Cost of U.S. Pharmaceutical Price Reduction
Thomas A. Abbott, John Vernon, NBER Working Paper Program No. 11114, 2-1-05

The authors find that pharmaceutical price controls “will significantly diminish the incentives to undertake early stage R&D investment.” They estimate that “cutting prices 40 to 50 percent in the U.S.” will lead firms to have “30 to 60 percent fewer R&D projects” in early-stage development.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000